Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27944480 | 0.98 | TDP1 (0.51) | TDP1LMNAMAPK1HIF1AITGB3 | |
| SCHEMBL27725512 | 0.91 | TDP1 (0.58) | TDP1LMNAMAPK1HIF1AITGB3 | |
| SCHEMBL27893702 | 0.91 | KMT2A (0.53) | TDP1LMNAMAPK1HIF1AKMT2A | |
| SCHEMBL14402754 | 0.89 | TDP1 (0.61) | TDP1LMNAMAPK1HIF1AKMT2A | |
| SCHEMBL18759619 | 0.89 | TDP1 (0.61) | TDP1LMNAMAPK1HIF1AKMT2A | |
| SCHEMBL8430060 | 0.89 | TDP1 (0.59) | TDP1LMNAITGB3ITGA2BSCN1A | |
| SCHEMBL28001475 | 0.85 | HTR7 (0.45) | KMT2AMEN1CHRM2CHRM1CHRM3 | |
| SCHEMBL27937189 | 0.85 | CHRNB2 (0.44) | LMNAITGB3ITGA2BKMT2ACHRM2 | |
| SCHEMBL27895732 | 0.85 | LMNA (0.50) | LMNAITGB3ITGA2BSLC6A3CHRM2 | |
| SCHEMBL27855837 | 0.85 | ITGB3 (0.44) | ITGB3ITGA2BKMT2AGBA1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-20 | — | — | US | disclosed |
| US-11897890-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-13 | — | — | US | disclosed |
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-11242347-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2022-02-08 | — | — | US | disclosed |
| US-11242347-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3124114-A1 | TRANSESTERIFICATION REACTION BY MEANS OF IRON CATALYST | Kyushu University, National University Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| CN-102471277-B | Heterocyclic compounds for killing microorganisms | SYNGENTA PARTICIPATIONS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-104487435-A | Benzodioxanes in combination with other actives for inhibiting leukotriene production | BOEHRINGER INGELHEIM INT | 2015-04-01 | — | — | CN | disclosed |
| US-20130190502-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| CN-102471277-A | Heterocyclic compounds for killing microorganisms | SYNGENTA PARTICIPATIONS AG | 2012-05-23 | — | — | CN | disclosed |
| EP-2196451-A1 | ACYLATION REACTION OF HYDROXYL GROUP | Takasago International Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, GNAO1, PDE3A | TDP1 674/4885LMNA 2511/4885MAPK1 1229/4885 |
| US-11242347-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, PDE3A, CHRM3 | TDP1 579/4885LMNA 2605/4885MAPK1 1670/4885 |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | TDP1 66/4885LMNA 1162/4885MAPK1 1878/4885 |
| US-20130190502-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | TDP1 4433/4885LMNA 4766/4885MAPK1 4580/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TDP1 2128/4885LMNA 2227/4885MAPK1 1312/4885 |
| US-11897890-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | TDP1 674/4885LMNA 2511/4885MAPK1 1229/4885 |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE5A, PDE1A, PDE2A | TDP1 66/4885LMNA 1162/4885MAPK1 1878/4885 |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | TDP1 66/4885LMNA 1162/4885MAPK1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.